The therapeutic algorithm of renal cell carcinoma has been revolutionized by the approval of
immunotherapy agents by regulatory agencies. However, objective and durable responses …

Objective: This study aimed to compare the safety profile of tyrosine kinase inhibitors (TKIs)
approved for use as monotherapy or combination therapy for the first-line treatment of adult …

Background Effective adjuvant therapy for patients with resected localised renal cell
carcinoma represents an unmet need, with surveillance being the standard of care. We …

Background Few treatment options are available for patients with advanced renal cell
carcinoma who have received previous anti-PD-1-based or anti-PD-L1-based …

Previous analyses of KEYNOTE-426, an open-label, phase 3 randomized study, showed
superior efficacy of first-line pembrolizumab plus axitinib to sunitinib in advanced clear cell …

Background Results from the phase 3 CLEAR study showed that lenvatinib plus
pembrolizumab improved progression-free survival and overall survival compared with …

Background Improved markers for predicting recurrence are needed to stratify patients with
localised (stage I–III) renal cell carcinoma after surgery for selection of adjuvant therapy. We …

Background Although, micropeptides encoded by non-coding RNA have been shown to
have an important role in a variety of tumors processes, there have been no reports on …

Context In the oncology setting, patient-reported outcome measures (PROMs) provide
important data that help to ensure patient-relevant endpoints are captured and reported. Use …

Renal clear cell carcinoma (ccRCC) comprises over 75% of all renal tumors and arises in
the epithelial cells of the proximal convoluted tubule. Molecularly ccRCC is characterized by …